Stifel initiates coverage on Olema Pharmaceuticals (OLMA) with buy rating
Stifel has initiated coverage on Olema Pharmaceuticals (OLMA) with a "buy" rating. This indicates a positive outlook from the investment bank regarding the company's stock. Further details on the price target or specific reasons for the rating are not available in this brief update.
From Olema to Insmed: Do These Soaring Biotechs Still Present a Good Investment Opportunity?
The biotech sector is seeing significant stock surges and advancements, with companies like Olema Pharmaceuticals reaching new 52-week highs due to positive trial results and strategic offerings. Wall Street analysts forecast a rise in OLMA stock price, initiating "Buy" ratings based on the strong market opportunity for its lead asset, palazestrant, in breast cancer treatment. Investors are also considering options contracts for OLMA, highlighting potential yield and return opportunities, alongside discussions of recent executive changes and the company's financial stability.
Olema Pharmaceuticals CEO Teases Fall OPERA-01 Readout, Q2 KAT6 Data and CFO/COO Exit
Olema Pharmaceuticals CEO Sean Bohen provided updates on the company's pipeline, including an expected Fall readout for the OPERA-01 trial of palazestrant and Q2 2026 data for the KAT6 inhibitor OP-3136. Bohen also addressed the departure of CFO/COO Shane Kovacs, framing it as the company prepares for potential commercialization of palazestrant in the U.S. and seeks ex-U.S. partners. He emphasized palazestrant's potential as a best-in-class oral SERD, citing its pharmacologic attributes and past clinical results.
Is Olema (OLMA) Balancing Leadership Change and New Wall Street Attention to Refine Its Strategy?
Olema Pharmaceuticals recently announced CFO Shane Kovacs' departure, with CEO Dr. Sean P. Bohen stepping in temporarily. Simultaneously, Stifel initiated analyst coverage with a positive outlook for the company, ahead of Olema's presentation at Guggenheim Securities’ Biotech Summit. Despite this new Wall Street attention, the company faces core risks including ongoing cash burn, trial outcomes, and the challenge of transitioning a young management team towards commercialization, especially with the uncertainty surrounding a new finance leader.
This Olema Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday
This article highlights four new analyst initiations for Wednesday, February 11, 2026. Stifel analyst Laura Prendergast initiated coverage on Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy rating and a $48 price target. Other companies receiving new coverage include Entrada Therapeutics (NASDAQ:TRDA), BridgeBio Oncology Therapeutics (NASDAQ:BBOT), and Energy Fuels Inc. (AMEX:UUUU), all with Buy ratings and new price targets.
Olema Pharmaceuticals (NASDAQ:OLMA) Now Covered by Analysts at Stifel Nicolaus
Stifel Nicolaus initiated coverage on Olema Pharmaceuticals (OLMA) with a "buy" rating and a $48 price target, indicating a significant upside. This latest coverage adds to a consensus of "Moderate Buy" among several firms, with an average target price of $41.78. Despite heavy insider selling of 765,501 shares worth $22.05 million over the past three months, insiders still own 16.36% of the company, and institutional ownership stands at 91.78%.
Stifel initiates Olema Pharmaceuticals stock with Buy rating, $48 target By Investing.com
Stifel initiated coverage on Olema Pharmaceuticals (OLMA) with a Buy rating and a $48 price target, citing the potential of its lead asset, palazestrant, as a "best-in-class oral SERD/CERAN" with projected peak sales of $3.1 billion by 2035. The positive outlook is supported by recent coverage initiations from Piper Sandler and UBS, also with Buy/Overweight ratings and price targets of $40-$45. This comes amidst a leadership change, with the COO/CFO departing and the CEO taking on interim financial officer duties while the company searches for a replacement.
Olema Pharmaceuticals, Inc. Rings the Closing Bell
Olema Pharmaceuticals, Inc. (Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on breast cancer therapies, visited the Nasdaq MarketSite in Times Square. The company's President and CEO, Sean Bohen, rang the Closing Bell to commemorate the occasion. The event took place on February 10, 2026, from 3:45 PM to 4:15 PM ET.
Olema Oncology to Participate in Upcoming Investor Conferences
Olema Pharmaceuticals, Inc. (Nasdaq: OLMA), a clinical-stage biopharmaceutical company, announced its participation in three upcoming investor conferences in February 2026: Guggenheim Securities Emerging Outlook: Biotech Summit, Citi’s 2026 Virtual Oncology Leadership Summit, and Oppenheimer's 36th Annual Healthcare Life Sciences Conference. The company specializes in targeted therapies for breast cancer, with lead product candidate palazestrant and a KAT6 inhibitor, OP-3136, currently in clinical trials. Webcasts of these presentations will be available on Olema's investor relations website.
Olema Pharmaceuticals seeks NDA lead for biotech program
Olema Pharmaceuticals is actively recruiting a Senior Director of Program Management to serve as the NDA Lead, a critical role focused on guiding the development and regulatory submission of its primary product candidate. This position highlights the company's dedication to advancing its pipeline and ensuring regulatory compliance. The individual hired will be crucial in bringing new therapies to market within the biotech sector.
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Consensus Rating of "Moderate Buy" by Analysts
Olema Pharmaceuticals (NASDAQ:OLMA) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $41.00. Despite this positive outlook, notable insider selling has occurred, with insiders offloading 765,501 shares worth approximately $22.05 million in the last quarter. The company opened at $25.01 with a market cap of $1.72 billion and reported a quarterly EPS of -$0.49, missing analyst estimates.
Institutional Investors Control 63% of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) and Were Rewarded Last Week After Stock Increased 7.2%
Institutional investors hold a substantial 63% stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA), indicating significant influence over the company's stock price. Their holdings benefited from a 7.2% stock increase last week, adding to a strong one-year return of 297% for shareholders. The top 9 shareholders collectively own 51% of the company, with private equity firms and hedge funds also holding notable percentages.
Breast cancer drug developer Olema lines up three investor talks
Olema Oncology (Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on breast cancer therapies, announced its participation in three investor conferences in February 2026. The company will hold fireside chats at the Guggenheim Emerging Outlook: Biotech Summit on February 11, Citi’s Virtual Oncology Leadership Summit on February 19, and the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26. Webcasts and recordings will be available on Olema's investor relations website as permitted by the event hosts.
Olema Pharmaceuticals to Present at Upcoming Investor Conferences in February 2026
Olema Pharmaceuticals, Inc. will present at three investor conferences in February 2026: the Guggenheim Securities Emerging Outlook: Biotech Summit, the Citi 2026 Virtual Oncology Leadership Summit, and the Oppenheimer 36th Annual Healthcare Life Sciences Conference. The presentations will be fireside chats available via webcast on Olema's investor relations website. The company is advancing palazestrant (OP-1250) in Phase 3 trials and OP-3136 in a Phase 1 study for breast cancer therapies.
Olema Oncology to Participate in Upcoming Investor Conferences
Olema Oncology announced its participation in three upcoming investor conferences in February 2026: Guggenheim Securities Emerging Outlook: Biotech Summit, Citi’s 2026 Virtual Oncology Leadership Summit, and Oppenheimer 36th Annual Healthcare Life Sciences Conference. The company, a clinical-stage biopharmaceutical firm focusing on breast cancer therapies, will present in fireside chat formats. Webcasts of these presentations will be available on Olema's investor relations website.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology announced it granted stock options for 24,000 shares to two new employees, effective February 2, 2026. These inducement grants, approved by the Compensation Committee, are in accordance with Nasdaq Listing Rule 5635(c)(4) and vest over four years. The exercise price for these options is $25.65 per share.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology announced that it granted stock options to two new employees to purchase an aggregate of 24,000 shares of the company's common stock. These grants were made under the company's 2022 Inducement Plan and are in accordance with Nasdaq Listing Rule 5635(c)(4) as an inducement for employment. The stock options vest over four years, have a 10-year term, and an exercise price of $25.65 per share.
Short Interest in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Decreases By 12.5%
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) experienced a significant 12.5% decrease in short interest in January, totaling 9,100,561 shares, which represents 15.8% of its shares sold short and a 6.3-day short-interest ratio. Despite broadly positive analyst sentiment with a "Moderate Buy" rating and a $41 average price target, the company saw substantial insider selling, with two insiders offloading 100,000 shares each at around $28, contributing to $22.05 million in insider sales over three months. The company's stock currently trades at $25.65, with a market capitalization of $1.76 billion, and institutional investors and hedge funds own 91.78% of the stock.
A Look At Olema Pharmaceuticals (OLMA) Valuation After Renewed Buy Ratings And Phase 3 Breast Cancer Plans
Olema Pharmaceuticals (OLMA) is gaining attention due to renewed analyst "buy" ratings and its ongoing Phase 3 breast cancer pipeline, with key clinical milestones expected through 2026. While the stock has seen significant momentum, its Price/Book ratio of 6.6x appears high compared to the industry average but is more restrained against its peer group, reflecting both enthusiasm for its pipeline and its current unprofitability. A Discounted Cash Flow analysis suggests the stock might be trading about 15.5% below its estimated future cash flow value, indicating potential upside despite the rich P/B valuation.
A Look At Olema Pharmaceuticals (OLMA) Valuation After Renewed Buy Ratings And Phase 3 Breast Cancer Plans
Olema Pharmaceuticals (OLMA) has seen its valuation discussed following renewed buy ratings and plans for Phase 3 breast cancer trials. Despite a significant 205% 90-day share price return, analysts suggest the stock might still be undervalued based on discounted cash flow models, trading about 15.5% below an estimated future cash flow value. However, its price-to-book ratio of 6.6x is higher than the broader US biotech average, indicating a premium assigned to its cancer programs even as the company remains unprofitable.
Olema Oncology Announces Departure of Chief Operating and Financial Officer
Olema Pharmaceuticals, Inc. announced that Shane Kovacs, Chief Operating and Financial Officer, is departing the company effective January 30, 2026, to pursue new opportunities. Mr. Kovacs will continue as a consultant until August 1, 2026, and Dr. Sean P. Bohen, President and CEO, has assumed the role of interim Principal Financial Officer while the company searches for a new CFO.
Olema Pharmaceuticals CFO Departs; CEO Assumes Interim Role
Olema Pharmaceuticals announced that Chief Operating and Financial Officer Shane Kovacs departed the company on January 30, 2026, to pursue new opportunities, but will remain as a consultant until August 1, 2026, receiving a $621,283 lump sum. CEO Sean Bohen will assume the interim principal financial officer role as the company searches for a new CFO, with the company noting Kovacs’ departure was not due to financial disagreements. An analyst currently rates OLMA stock as a Buy with a $29.00 price target, while TipRanks' AI Analyst "Spark" rates it Neutral due to weak financial performance despite strong technical trends and clinical updates.
Breast cancer-focused Olema sees financial officer depart, CEO steps in
Olema Oncology announced that its Chief Operating and Financial Officer, Shane Kovacs, is departing effective January 30, 2026, to pursue new opportunities. President and CEO Sean P. Bohen has assumed the interim Principal Financial Officer role while the company searches for a successor. Kovacs will remain as a consultant until August 1, 2026, and is credited with advancing palazestrant and establishing a strong capital position for the company.
Olema Oncology Announces Departure of Chief Operating and Financial Officer
Olema Pharmaceuticals, Inc. announced the departure of Shane Kovacs, its Chief Operating and Financial Officer, effective January 30, 2026. Mr. Kovacs will continue in a consulting capacity until August 1, 2026, and the company has begun a search for a new CFO, with President and CEO Dr. Sean P. Bohen serving as interim Principal Financial Officer. The company acknowledged Kovacs' significant contributions since 2020 in leading growth, progressing palazestrant, and establishing a strong capital position.
Olema (NASDAQ: OLMA) CFO exits with $621,283 package as CEO steps in
Olema Pharmaceuticals announced that CFO Shane Kovacs is departing the company effective January 30, 2026, though he will remain as a consultant until August 1, 2026, with his equity awards continuing to vest. He will receive a lump-sum payment of $621,283, comprising 12 months of base salary, a pro-rated 2026 target bonus, and COBRA health coverage gross-up. CEO Sean Bohen will serve as interim principal financial officer, and the company stated Kovacs's departure is not due to any financial disagreements.
Olema Pharmaceuticals CFO Departs; CEO Assumes Interim Role
Olema Pharmaceuticals announced the departure of its COO and CFO, Shane Kovacs, on January 30, 2026. CEO Sean Bohen will temporarily take over principal financial officer duties while the company searches for a new CFO. Kovacs will remain as a consultant, continuing to vest equity awards and receiving a lump-sum payment, with the company clarifying his departure was not due to financial disagreements.
Olema Oncology Announces Departure of Chief Operating and Financial Officer
Olema Oncology announced that Shane Kovacs, Chief Operating and Financial Officer, is departing the company effective January 30, 2026, to pursue new opportunities. Mr. Kovacs will continue in a consulting capacity until August 1, 2026. Sean P. Bohen, M.D., Ph.D., President and CEO, will serve as interim Principal Financial Officer while the company searches for a successor.
LifeSci Capital Reiterates a Buy on Olema Pharmaceuticals (OLMA)
LifeSci Capital has reiterated a Buy rating on Olema Pharmaceuticals (OLMA) and increased its price target to $45, following a similar bullish outlook from Piper Sandler. Both firms highlight the potential of Palazestrant, a drug for ER+/HER2- breast cancer, citing its expected 2026 launch and upcoming phase 3 trials. Olema Pharmaceuticals focuses on developing treatments for breast cancer, with Palazestrant and OP-3136 as key pipeline assets.
LifeSci Capital Reiterates a Buy on Olema Pharmaceuticals (OLMA)
LifeSci Capital reiterated a Buy rating on Olema Pharmaceuticals (OLMA) and raised its price target from $39 to $45, following Piper Sandler's earlier reiteration of a Buy with a $40 price target. The bullish sentiment is driven by the potential of Olema's drug Palazestrant for treating ER+/HER2- breast cancer, with expectations for multiple phase 3 trials in 2026 and a possible launch by next year.
LifeSci Capital Reiterates a Buy on Olema Pharmaceuticals (OLMA)
LifeSci Capital has reiterated a Buy rating on Olema Pharmaceuticals (OLMA), raising its price target to $45. This positive outlook is primarily driven by the company's drug Palazestrant, a potential best-in-class treatment for ER+/HER2- breast cancer, which is expected to launch next year. Analysts anticipate further upside from multiple Phase 3 trials in 2026.
Olema Oncology CFO Shane Kovacs to depart after six-year tenure
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) announced that Chief Operating and Financial Officer Shane Kovacs will depart on January 30, 2026, after six years. Kovacs played a key role in guiding the clinical development of palazestrant and strengthening the company’s finances. President and CEO Dr. Sean P. Bohen will assume the role of Principal Financial Officer while the company searches for a successor, with Kovacs remaining as a consultant until August 1, 2026.
Olema Pharmaceuticals (OLMA) stock jumps 6% in a weak market — what to watch next
Olema Pharmaceuticals (OLMA) saw its stock jump 6% defying a broader market downturn, driven by anticipation surrounding its late-stage palazestrant trial for hormone-driven breast cancer. The company maintains a strong cash position exceeding $500 million and expects top-line data from its OPERA-01 Phase 3 trial and initial clinical results for OP-3136 in mid to late 2026. Investors are now focused on Olema's upcoming earnings report in March for updates on its clinical trials and burn rate.
10 Best Small-Cap Stocks Ready to Explode in 2026
This article identifies Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) as one of the top small-cap stocks poised for significant growth in 2026. Analysts reiterated "Buy" ratings and increased price targets for OLMA, citing its drug Palazestrant, a potential best-in-class treatment for ER+/HER2- breast cancer. The company expects multiple Phase 3 trials in 2026 and a Palazestrant launch by next year, which are anticipated to drive stock upside.
SEC Enforcement Action Targets Insider Trading in the Pharmaceutical Industry
The SEC has filed a complaint against several defendants for alleged market manipulation and insider trading schemes involving pharmaceutical companies Olema Pharmaceuticals, Inc. and Opiant Pharmaceuticals, Inc. The schemes included "pump and dump" tactics by falsifying clinical trial results and using misappropriated material nonpublic information (MNPI) for insider trading. This action underscores the severe risks faced by biopharmaceutical companies and emphasizes the need for robust internal safeguards and vigilance to prevent improper trading and the spread of deceptive information.
Harmon Cyrus, director at Olema, sells $268,800 in stock
Olema Pharmaceuticals director Harmon Cyrus sold 10,000 shares of the company's common stock for $268,800 on January 20, 2026, with the stock trading between $26.85 and $26.96. This transaction follows a significant 362.85% price surge for OLMA over the past year. Analysts maintain a strong buy consensus, and several investment firms have recently raised their price targets for Olema Pharmaceuticals, citing promising developments in its breast cancer treatment palazestrant.
Olema Pharmaceuticals (NASDAQ:OLMA) Director Cyrus Harmon Sells 10,000 Shares
Olema Pharmaceuticals director Cyrus Harmon sold 10,000 shares of the company's stock on January 20th for $268,800, reducing his direct ownership by 1.36%. This transaction follows other recent sales by Harmon in January and December. The stock traded down 1.6% at $26.29, and analysts have a "Moderate Buy" rating with an average target price of $41.
Harmon Cyrus, director at Olema, sells $268,800 in stock
Olema Pharmaceuticals director Harmon Cyrus sold 10,000 shares of common stock for $268,800 on January 20, 2026. This transaction follows a significant 362.85% price surge for the company's stock over the past year, with analysts maintaining a strong buy consensus. Multiple investment firms have recently initiated or upgraded coverage on Olema, citing the potential of its breast cancer treatment, palazestrant.
Olema Pharmaceuticals (NASDAQ:OLMA) Director Cyrus Harmon Sells 3,489 Shares
Olema Pharmaceuticals (NASDAQ:OLMA) Director Cyrus Harmon sold 3,489 shares of the company's stock on January 14th at an average price of $29.12, totaling over $101,599. This transaction reduced his stake by 0.47% to 737,770 shares. The company has a current market capitalization of $1.86 billion and an average analyst target price of $41.00, with many research firms issuing "buy" ratings.
A Look At Olema Pharmaceuticals (OLMA) Valuation After Fresh Bullish Analyst Coverage And Conference Spotlight
Olema Pharmaceuticals (OLMA) is gaining attention due to recent bullish analyst coverage and an upcoming presentation, highlighting its breast cancer drug pipeline. Despite a recent share price dip, the stock has seen significant gains over the past year, trading at a price-to-book ratio of 6.9x, which is below its peer average but above the broader US Biotechs industry. A discounted cash flow model suggests the stock is currently trading at a slight discount of about 9.4% to its estimated fair value.
A Look At Olema Pharmaceuticals (OLMA) Valuation After Fresh Bullish Analyst Coverage And Conference Spotlight
Olema Pharmaceuticals (OLMA) is gaining attention due to new bullish analyst coverage and an upcoming presentation at the J.P. Morgan Healthcare Conference, focusing on its breast cancer drug pipeline. Despite a recent share price dip, the stock has shown significant momentum over the past year. The article analyzes Olema's valuation, noting its P/B ratio of 6.9x is below its peer average but above the broader industry, and suggests a slight discount based on a DCF model, while highlighting the importance of trial success and funding.
Olema Pharmaceuticals director Harmon sells $101k in stock By Investing.com
Olema Pharmaceuticals director Cyrus Harmon sold 3,489 shares of common stock for $101,599 on January 14, 2026. This transaction occurred while OLMA shares have seen significant growth and are considered slightly overvalued. The company maintains a strong financial position, and several investment firms have initiated positive coverage for its lead breast cancer drug, palazestrant.
Olema Pharmaceuticals director Harmon sells $101k in stock
Olema Pharmaceuticals director Cyrus Harmon sold 3,489 shares of common stock for $101,599 on January 14, 2026. This transaction occurred after the company's shares delivered a 379.51% return over the past year. The stock is currently trading near its 52-week high, and several investment firms have initiated or raised price targets for Olema Pharmaceuticals, citing positive developments in its drug pipeline.
Olema Pharmaceuticals director Harmon sells $101k in stock
Olema Pharmaceuticals director Cyrus Harmon sold 3,489 shares of company stock for a total of $101,599. The sale occurred while OLMA shares have seen significant growth, and the company maintains a strong financial position. Several investment firms have recently initiated or increased coverage on Olema Pharmaceuticals, citing potential in its breast cancer treatment pipeline.
Olema Pharma CFO Kovacs sells shares worth $2.98 million
Olema Pharmaceuticals, Inc.'s Chief Operating and Financial Officer, Shane William Charles Kovacs, sold 103,822 shares of common stock in two transactions totaling $2.98 million. Despite these sales, Kovacs still directly owns 139,727 shares. The company, which has a market capitalization of $2.27 billion, is unprofitable but holds a strong financial position with more cash than debt.
Insider Sell Alert: Kovacs Shane William Charles Sells Shares of Olema Pharmaceuticals Inc (OLMA)
Kovacs Shane William Charles, the Chief Operating & Financial Officer of Olema Pharmaceuticals Inc (OLMA), sold 103,822 shares of the company on January 15, 2026. This transaction continues a trend of insider selling activity over the past year, with no insider buys recorded. Investors are advised to consider various valuation metrics for OLMA, which was trading at $28.70 per share following the sale.
Insider Selling: Olema Pharmaceuticals (NASDAQ:OLMA) Insider Sells 3,822 Shares of Stock
Olema Pharmaceuticals (NASDAQ:OLMA) insider Shane William Charles Kovacs sold 3,822 shares on January 13th for $107,054.22 and an additional 100,000 shares on January 15th for $2,873,000.00, reducing his ownership by 1.57% to 239,727 shares. Despite these insider sales, Wall Street analysts maintain a "Moderate Buy" consensus rating with a target price of $41.00 for the clinical-stage biopharmaceutical company. The company reported a market capitalization of $2.00 billion, with 91.78% institutional ownership, and analysts anticipate negative earnings per share for the current fiscal year.
Insider Selling: Olema Pharmaceuticals (NASDAQ:OLMA) Insider Sells 100,000 Shares of Stock
Shane William Charles Kovacs, an insider at Olema Pharmaceuticals (NASDAQ:OLMA), sold 100,000 shares of the company's stock on January 15th for a total value of $2,873,000.00. This transaction reduced his stake by 41.71%, leaving him with 139,727 shares. The company's stock rose 1.5% to $29.19 on Thursday, and analysts currently rate OLMA as a "Moderate Buy" with an average price target of $41.00.
Olema Pharma CFO Kovacs sells shares worth $2.98 million
Olema Pharmaceuticals' CFO, Shane William Charles Kovacs, sold 103,822 shares of common stock in two transactions totaling $2.98 million. Despite the sales, the company maintains a strong financial position, and analysts remain bullish with price targets ranging from $38 to $60, largely due to promising developments in its breast cancer treatment pipeline. The stock has shown significant performance, with a 452.84% return over the past year.
Wall Street Remains Bullish on Olema Pharmaceuticals Inc. (OLMA)
Wall Street analysts are bullish on Olema Pharmaceuticals Inc. (OLMA) after UBS and Piper Sandler initiated coverage with Buy and Overweight ratings, respectively, and set price targets of $45 and $40. This optimism is driven by promising clinical data for the company's Palazestrant drug for breast cancer and a perceived shift in the biotech sector's fundamentals. Analysts anticipate an average share price appreciation of 46% over the next 12 months.
Olema Pharmaceuticals (NASDAQ:OLMA) Insider David Myles Sells 10,000 Shares
Olema Pharmaceuticals (NASDAQ:OLMA) insider David Myles sold 10,000 shares of the company's stock for $283,400 on January 12th, decreasing his position by 6.46%. Despite this insider sale, the company maintains a "Moderate Buy" consensus rating from analysts, with an average target price of $41.00 following recent upgrades. The stock is currently trading at $28.77 with a market cap of $1.98 billion and substantial institutional ownership.
